Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
Portfolio Pulse from Vandana Singh
The World Health Organization (WHO) has published new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which include new medicines for various diseases. However, Novo Nordisk's obesity drug Saxenda was not included due to uncertain long-term clinical benefit and safety. Other drugs included in the list are from EMD Serono, Merck KGaA, Teva Pharmaceuticals, Roche Holdings, Ridgeback Biotherapeutics, and Regeneron Pharmaceuticals.
July 26, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck KGaA's cladribine branded Mavenclad was included in WHO's essential medicines list.
The inclusion of Mavenclad in the WHO's essential medicines list could positively impact Merck KGaA's market reach and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron Pharmaceuticals' Inmazeb was included in WHO's essential medicines list.
The inclusion of Inmazeb in the WHO's essential medicines list could positively impact Regeneron Pharmaceuticals' market reach and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Teva Pharmaceuticals' Copaxone was included in WHO's essential medicines list.
The inclusion of Copaxone in the WHO's essential medicines list could positively impact Teva Pharmaceuticals' market reach and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk's obesity drug Saxenda was not included in WHO's essential medicines list due to uncertain long-term clinical benefit and safety.
The exclusion of Saxenda from the WHO's essential medicines list could negatively impact Novo Nordisk's market reach and sales, especially in low- and middle-income countries.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100